Español
PDFs by language
Our 24/7 cancer helpline provides information and answers for people dealing with cancer. We can connect you with trained cancer information specialists who will answer questions about a cancer diagnosis and provide guidance and a compassionate ear.
Chat live online
Select the Live Chat button at the bottom of the page
Call us at 1-800-227-2345
Available any time of day or night
Our highly trained specialists are available 24/7 via phone and on weekdays can assist through online chat. We connect patients, caregivers, and family members with essential services and resources at every step of their cancer journey. Ask us how you can get involved and support the fight against cancer. Some of the topics we can assist with include:
For medical questions, we encourage you to review our information with your doctor.
Immunotherapy is the use of medicines that help a person’s own immune system find and destroy cancer cells. This is often a useful form of treatment for Merkel cell carcinoma (MCC), especially if it has spread to other parts of the body.
An important part of the immune system is its ability to keep itself from attacking normal cells in the body. To do this, it uses “checkpoint” proteins on immune cells, which act like switches that need to be turned on (or off) to start an immune response.
Cancer cells sometimes use these checkpoints to keep the immune system from attacking them. But drugs that target checkpoint proteins, called checkpoint inhibitors, can help the immune system find and attack cancer cells.
PD-1 is a checkpoint protein on immune cells called T cells. It normally helps keep the T cells from attacking other cells in the body. When it attaches to PD-L1, a protein on some normal (and cancer) cells, it basically tells the T cell to leave the other cell alone. Some cancer cells have large amounts of PD-L1, which helps keep the immune system from attacking them.
Drugs that block either PD-1 or PD-L1 can stop this binding and boost the body's immune response against cancer cells. Examples of checkpoint inhibitors that can be used to treat MCC include:
These drugs are given as an infusion into a vein (IV), usually every 2 to 6 weeks, depending on the drug.
These drugs can often shrink or slow the growth of advanced MCC tumors. Doctors are now studying the use of these drugs for some earlier-stage MCCs as well. For example, they are testing to see if these drugs might be useful after, or even before, surgery in some people.
Other immune checkpoint inhibitors are being studied for use against MCC as well.
Side effects of these types of drugs can include:
Other, more serious side effects occur less often:
Infusion reactions: Some people might have an infusion reaction while getting one of these drugs. This is like an allergic reaction. It can include fever, chills, flushing of the face, rash, itchy skin, wheezing, and trouble breathing. It’s important to tell your doctor or nurse right away if you have any of these symptoms while getting these drugs.
Autoimmune reactions: These drugs work by removing one of the safeguards that helps keep the body’s immune system in check. Sometimes this can lead to the immune system attacking other parts of the body, which can cause serious or even life-threatening problems in the lungs, intestines, liver, hormone-making glands, kidneys, or other organs.
It’s very important to report any changes or new side effects to your health care team right away. If serious side effects do occur, you might need to stop treatment.
To learn more about how drugs that work on the immune system are used to treat cancer, see Cancer Immunotherapy.
To learn about some of the side effects listed here and how to manage them, see Managing Cancer-related Side Effects.
The American Cancer Society medical and editorial content team
Our team is made up of doctors and oncology certified nurses with deep knowledge of cancer care as well as editors and translators with extensive experience in medical writing.
National Cancer Institute. Merkel Cell Carcinoma Treatment (PDQ)–Health Professional Version. 2024. Accessed at https://www.cancer.gov/types/skin/hp/merkel-cell-treatment-pdq on May 28, 2024.
National Comprehensive Cancer Network.NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Merkel Cell Carcinoma. Version 1.2024. Accessed at https://www.nccn.org on May 28, 2024.
Park SY, Nghiem PT, Tai P, Silk AW. Treatment of recurrent and metastatic Merkel cell carcinoma. UpToDate. 2024. Accessed at https://www.uptodate.com/contents/treatment-of-recurrent-and-metastatic-merkel-cell-carcinoma on May 28, 2024.
Tai P, Park SY, Nghiem PT, Silk AW. Staging, treatment, and surveillance of locoregional Merkel cell carcinoma. UpToDate. 2024. Accessed at https://www.uptodate.com/contents/staging-treatment-and-surveillance-of-locoregional-merkel-cell-carcinoma on May 28, 2024.
Last Revised: May 30, 2024
American Cancer Society medical information is copyrighted material. For reprint requests, please see our Content Usage Policy.
Sign up to stay up-to-date with news, valuable information, and ways to get involved with the American Cancer Society.
If this was helpful, donate to help fund patient support services, research, and cancer content updates.